A Two-part Phase I Randomized Double Blind (Sponsor Open) Placebo Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, Target Engagement and Potential for Efficacy of Single Intravenous and Subcutaneous Doses of GSK3858279 in Healthy Volunteers and Participants With Osteoarthritis of the Knee
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2018
At a glance
- Drugs GSK-3858279 (Primary) ; GSK-3858279 (Primary)
- Indications Pain
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 01 Jun 2018 Planned End Date changed from 13 Nov 2019 to 27 Nov 2019.
- 01 Jun 2018 Planned primary completion date changed from 13 Nov 2019 to 27 Nov 2019.